Patents by Inventor Zhuozhi Wang

Zhuozhi Wang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11078281
    Abstract: The present invention provides CTLA-4 monoclonal antibodies, particularly humanized monoclonal antibodies specifically binding to CTLA-4 with high affinity. The present invention also provides functional monoclonal antibodies cross-reactive to CTLA-4 of human, cynomolgus monkey and mouse. The present invention further provides amino acid sequences of the antibodies of the invention, cloning or expression vectors, host cells and methods for expressing or isolating the antibodies. The epitopes of the antibodies are identified. Therapeutic compositions comprising the antibodies of the invention are also provided. The invention also provides methods for treating cancers and other diseases with anti-CTLA-4 antibodies.
    Type: Grant
    Filed: August 6, 2020
    Date of Patent: August 3, 2021
    Assignee: WUXI Biologies (Shanghai) Co., Ltd.
    Inventors: Zhuozhi Wang, Jing Li, Gennady Gololobov, Jianqing Xu
  • Publication number: 20210115138
    Abstract: Anti-LAG-3/PD-1 bispecific antibody molecules, isolated polynucleotides encoding the same, pharmaceutical compositions comprising the same, and the uses thereof are provided.
    Type: Application
    Filed: March 19, 2019
    Publication date: April 22, 2021
    Applicant: WuXi Biologics Ireland Limited
    Inventors: Zhuozhi Wang, Yong Zheng, Jing Li, Qiong Wu
  • Publication number: 20210040214
    Abstract: The present invention provides CTLA-4 monoclonal antibodies, particularly humanized monoclonal antibodies specifically binding to CTLA-4 with high affinity. The present invention also provides functional monoclonal antibodies cross-reactive to CTLA-4 of human, cynomolgus monkey and mouse. The present invention further provides amino acid sequences of the antibodies of the invention, cloning or expression vectors, host cells and methods for expressing or isolating the antibodies. The epitopes of the antibodies are identified. Therapeutic compositions comprising the antibodies of the invention are also provided. The invention also provides methods for treating cancers and other diseases with anti-CTLA-4 antibodies.
    Type: Application
    Filed: August 6, 2020
    Publication date: February 11, 2021
    Inventors: Zhuozhi WANG, Jing LI, Gennady GOLOLOBOV, Jianqing XU
  • Publication number: 20200354460
    Abstract: The present invention provides bispecific antibodies comprising first binding domain which binds to EGFR and a second binding domain which binds to PD-1, wherein the antibody or the antigen binding-fragment is in a format selected from the group consisting of single chain Fv (scFv), diabodies, and oligomers of the foregoing formats. The present invention further provides amino acid sequences of the antibodies of the invention, cloning or expression vectors, host cells and methods for expressing or isolating the antibodies. Therapeutic compositions comprising the antibodies of the invention are also provided. The invention also provides methods for treating cancers and other diseases with the bispecific antibodies.
    Type: Application
    Filed: September 26, 2018
    Publication date: November 12, 2020
    Inventors: Zhuozhi WANG, Jing LI
  • Publication number: 20200283523
    Abstract: A bispecific anti-CD3×CD19 polypeptide complex that contains a first antigen-binding moiety of the polypeptide complex and a second antigen-binding moiety, methods of producing the bispecific anti-CD3×CD19 polypeptide complex, methods of treating disease or disorder using the bispecific anti-CD3×CD19 polypeptide complex, polynucleotides encoding the bispecific anti-CD3×CD19 polypeptide complex, vectors and host cells containing said polynucleotides, and compositions and pharmaceutical compositions comprising the bispecific anti-CD3×CD19 polypeptide complex are provided.
    Type: Application
    Filed: September 20, 2018
    Publication date: September 10, 2020
    Inventors: Jieying LIU, Jianqing XU, Zhuozhi WANG, Qin MEI, Jing LI
  • Publication number: 20200283524
    Abstract: A polypeptide complex comprises antibody variable regions of the heavy chain and light chain respectively fused to TCR constant regions. A bispecific antigen binding polypeptide complex contains a first antigen-binding moiety of the polypeptide complex and a second antigen-binding moiety. A method comprises producing the polypeptide complex or the bispecific antigen binding polypeptide complex. A method of treating disease or disorder comprises using the polypeptide complex or the bispecific antigen binding polypeptide complex. A polynucleotide encodes the polypeptide complex and/or the bispecific antigen binding polypeptide complex. A vector or a host cell contains the polynucleotide. A composition and a pharmaceutical composition comprise the polypeptide complex and/or the bispecific antigen binding polypeptide complex.
    Type: Application
    Filed: September 20, 2018
    Publication date: September 10, 2020
    Inventors: Jianqing XU, Zhuozhi WANG, Jing LI
  • Publication number: 20200277377
    Abstract: The present invention provides CTLA-4 monoclonal antibodies, particularly humanized monoclonal antibodies specifically binding to CTLA-4 with high affinity. The present invention also provides functional monoclonal antibodies cross-reactive to CTLA-4 of human, cynomolgus monkey and mouse. The present invention further provides amino acid sequences of the antibodies of the invention, cloning or expression vectors, host cells and methods for expressing or isolating the antibodies. The epitopes of the antibodies are identified. Therapeutic compositions comprising the antibodies of the invention are also provided. The invention also provides methods for treating cancers and other diseases with anti-CTLA-4 antibodies.
    Type: Application
    Filed: May 19, 2017
    Publication date: September 3, 2020
    Applicant: WUXI Biologics (Shanghai) Co., Ltd.
    Inventors: Zhuozhi WANG, Jing LI, Gennady GOLOLOBOV, Jianqing XU
  • Publication number: 20200002420
    Abstract: The present invention provides PD-1 monoclonal antibodies, particularly human monoclonal antibodies of PD-1, which specifically bind to PD-1 with high affinity and comprise a heavy chain and a light chain. The present invention further provides nucleic acid sequence encoding the antibodies of the invention, cloning or expression vectors, host cells and methods for expressing or isolating the antibodies. Immunoconjugates, therapeutic compositions comprising the antibodies of the invention are also provided. The invention also provides methods for treating various cancers with anti-PD-1 antibodies.
    Type: Application
    Filed: September 21, 2016
    Publication date: January 2, 2020
    Inventors: Yong ZHENG, Jing LI, Gennady GOLOLOBOV, Xinhua ZHANG, Baotian YANG, Zhewei TANG, Dong LI, Jianqing XU, Zhuozhi WANG
  • Publication number: 20190194353
    Abstract: Isolate monoclonal antibodies that bind to specific epitopes of human tissue factor pathway inhibitor (TFPI) and the isolated nucleic acid molecules encoding them are provided. Pharmaceutical compositions comprising the anti-TFPI monoclonal antibodies and methods of treating deficiencies or defects in coagulation by administration of the antibodies are also provided.
    Type: Application
    Filed: December 27, 2018
    Publication date: June 27, 2019
    Applicant: Bayer HealthCare LLC
    Inventors: Zhuozhi WANG, John MURPHY, Tobias MARQUARDT, Dieter MOOSMAYER
  • Publication number: 20180334509
    Abstract: Isolated monoclonal antibodies that bind human tissue factor pathway inhibitor (TFPI) and the isolated nucleic acid molecules encoding them are provided. Pharmaceutical compositions comprising the anti-TFPI monoclonal antibodies and methods of treating deficiencies or defects in coagulation by administration of the antibodies are also provided. Methods of producing the antibodies are also provided.
    Type: Application
    Filed: June 4, 2018
    Publication date: November 22, 2018
    Applicant: Bayer HealthCare LLC
    Inventors: Zhuozhi WANG, John E. MURPHY, Junliang PAN, Haiyan Jiang, Bing LIU
  • Publication number: 20180282430
    Abstract: Antibodies are disclosed that bind to and inhibit the anti-coagulant function of TFPI and have a lower affinity for TFPi at pH 6.0 than at pH 7.4. The lower affinity at pH 6 improves circulating half-life (T1/2) due to reduced target mediated clearance, a process by which an antibody/antigen complex, is endocytased and trafficked to the lysosome where both components are degraded. The lower affinity at pH 6.0 results in disruption of the complex prior to lysosome targeting and allows for re-circulation of the antibody. Specific modifications to antibody binding by histidine residue substitution are disclosed along with methods of use.
    Type: Application
    Filed: April 25, 2018
    Publication date: October 4, 2018
    Applicant: BAYER HEALTHCARE LLC
    Inventors: John E. Murphy, Zhuozhi Wang, Ruth Winter
  • Publication number: 20180251570
    Abstract: This disclosure provides protease-regulated antibodies which specifically bind to tissue factor pathway inhibitor (TFPI). The antibodies are useful for treating bleeding disorders such as hemophilia.
    Type: Application
    Filed: May 16, 2018
    Publication date: September 6, 2018
    Applicant: BAYER HEALTHCARE LLC
    Inventors: Zhuozhi WANG, Ruth WINTER, John MURPHY
  • Publication number: 20180194857
    Abstract: Isolated monoclonal antibodies that bind to specific epitopes of human tissue factor pathway inhibitor (TFPI) and the isolated nucleic acid molecules encoding them are provided. Pharmaceutical compositions comprising the anti-TFPI monoclonal antibodies and methods of treating deficiencies or defects in coagulation by administration of the antibodies are also provided.
    Type: Application
    Filed: January 22, 2018
    Publication date: July 12, 2018
    Inventors: Zhuozhi WANG, John MURPHY, Tobias MARQUARDT, Dieter MOOSMAYER
  • Patent number: 9975962
    Abstract: This disclosure provides protease-regulated antibodies which specifically bind to tissue factor pathway inhibitor (TFPI). The antibodies are useful for treating bleeding disorders such as hemophilia.
    Type: Grant
    Filed: March 14, 2013
    Date of Patent: May 22, 2018
    Assignee: BAYER HEALTHCARE LLC
    Inventors: Zhuozhi Wang, Ruth Winter, John Murphy
  • Publication number: 20170342162
    Abstract: Isolated monoclonal antibodies that bind human tissue factor pathway inhibitor (TFPI) and the isolated nucleic acid molecules encoding them are provided. Pharmaceutical compositions comprising the anti-TFPI monoclonal antibodies and methods of treating deficiencies or defects in coagulation by administration of the antibodies are also provided. Methods of producing the antibodies are also provided.
    Type: Application
    Filed: July 7, 2017
    Publication date: November 30, 2017
    Applicant: Bayer HealthCare LLC
    Inventors: Zhuozhi WANG, John E. MURPHY, Junliang PAN, Haiyan Jiang, Bing LIU
  • Publication number: 20170210825
    Abstract: This invention relates to monospecific and multispecific antibodies that may be utilized for the diagnosis and treatment of various diseases. In addition, these antibodies may be modified by protease cleavage. Protease control or regulation may be provided by a protease site located in, for example, a linker. These protease-regulated antibodies may also be utilized for the diagnosis and treatment of various diseases.
    Type: Application
    Filed: March 22, 2017
    Publication date: July 27, 2017
    Inventors: Bing LIU, David LIGHT, Zhuozhi WANG, Douglas SCHNEIDER
  • Patent number: 9657111
    Abstract: Provided are humanized antibodies that selectively bind to and inhibit activated protein C without binding to or inhibiting unactivated protein C. Methods of treatment employing these antibodies are described herein.
    Type: Grant
    Filed: November 27, 2013
    Date of Patent: May 23, 2017
    Assignee: BAYER HEALTHCARE LLC
    Inventors: Xiao-Yan Zhao, Zhuozhi Wang, Ji-Yun Kim, Ying Zhu, Jan Tebbe
  • Publication number: 20170107298
    Abstract: Isolated monoclonal antibodies that bind to specific epitopes of human tissue factor pathway inhibitor (TFPI) and the isolated nucleic acid molecules encoding them are provided. Pharmaceutical compositions comprising the anti-TFPI monoclonal antibodies and methods of treating deficiencies or defects in coagulation by administration of the antibodies are also provided.
    Type: Application
    Filed: July 27, 2016
    Publication date: April 20, 2017
    Inventors: Zhuozhi WANG, John E. MURPHY, Tobias MARQUARDT, Dieter MOOSMAYER
  • Patent number: 9624309
    Abstract: This invention relates to monospecific and multispecific antibodies that may be utilized for the diagnosis and treatment of various diseases. In addition, these antibodies may be modified by protease cleavage. Protease control or regulation may be provided by a protease site located in, for example, a linker. These protease-regulated antibodies may also be utilized for the diagnosis and treatment of various diseases.
    Type: Grant
    Filed: August 16, 2008
    Date of Patent: April 18, 2017
    Assignee: BAYER INTELLECTUAL PROPERTY GmbH
    Inventors: Bing Liu, David Light, Zhuozhi Wang, Douglas Schneider
  • Patent number: RE47150
    Abstract: Isolated monoclonal antibodies that bind human tissue factor pathway inhibitor (TFPI) are provided. Isolated nucleic acid molecules encoding monoclonal antibodies that bind TFPI are also contemplated. Pharmaceutical compositions comprising the anti-TFPI monoclonal antibodies and methods of treating deficiencies or defects in coagulation by administration of the antibodies are also provided. Methods of producing the antibodies are also provided.
    Type: Grant
    Filed: July 12, 2016
    Date of Patent: December 4, 2018
    Assignee: Bayer HealthCare LLC
    Inventors: Zhuozhi Wang, Junliang Pan, Joanna Grudzinska-Goebel, Christian Votsmeier, Jan Tebbe, Joerg Birkenfeld, Nina Wobst, Simone Brückner, Susanne Steinig, Peter Scholz